Patient dies in Bristol Myers Squibb autoimmune CAR-T trial

A patient has died in a Bristol Myers Squibb clinical trial testing CAR-T cell therapy for autoimmune disease, according to STAT News. The report, published October 23, is limited in the Specola’s sources to the bare fact of the death and the question it raises for the field: where the safety bar should sit for studies applying CAR-T engineering, originally developed for cancer, to autoimmune conditions.

STAT News flags the case as a test for an emerging area of medicine. CAR-T therapies work by re-engineering a patient’s own immune cells to recognize and attack a target, a technique that has produced durable remissions in some blood cancers. Researchers have more recently begun adapting the same approach for autoimmune disorders, conditions in which the immune system attacks the body’s own tissue rather than an external threat or tumor. The appeal is a potential reset of a misfiring immune system. The risk, as in oncology applications, includes severe immune activation and other toxicities that have proven fatal in some cancer trials.

The available source material does not specify the patient’s condition, the stage of the trial, the cause of death, or whether Bristol Myers Squibb has paused or altered the study. STAT News frames the death chiefly as raising a question for the field rather than resolving one. No company statement, regulatory response, or additional clinical detail is included in the cited report.